Zachary Hill
VP, Discovery Chemistry and protein-engineering-focused chemist
San Francisco, California
Summary
Expertise in protein engineering and chemically induced dimerizers — Hill's postdoctoral work in Jim Wells' lab focused on developing AbCID/LITE Switch technologies (human antibody-based chemically induced dimerizers) and other protein–small molecule tools to control cellular processes, work that underpins the technology translated at Soteria. nih+2
Translational focus on controllable cell- and T-cell-based therapies — Hill co-founded Soteria to apply protein-switch and AbCID approaches to create switchable bispecific T-cell engagers (T-LITE) aimed at safer, controllable oncology therapies. prnewswire+1
Academic recognition and funded training — while at UCSF Hill received prestigious support during his postdoctoral training, including a Helen Hay Whitney fellowship and an NCI K99/R00 award to study conformation-specific interactomes of signaling proteins. ucsf+1
Biotech leadership and startup experience — Hill has held discovery leadership roles in startups and biotech, including co-founding Soteria (2018) where he served in discovery leadership and CSO roles, and later joining Montara Therapeutics as a discovery chemistry leader. prnewswire+2
Work
Education
Projects
Writing
Human antibody-based chemically induced dimerizers for cell therapeutic applications
January 1, 2018Describes the development of human antibody-based chemically induced dimerizers (AbCIDs) derived from small-molecule–protein complexes and demonstrates their application to regulate gene expression and CAR T-cell activation, highlighting potential for regulating cell therapies.
Mapping the conformation-specific interactome of signaling proteins (NIH K99 proposal summary)
K99 award project summary proposing enzymatic-tagging coupled with quantitative proteomics to study how mutations and ligands change the interactome of signaling proteins such as BRAF and KRAS in living cells.